CY1113594T1 - Φουμαρικο αλας της (αλφα s, βητα r)-6-βρωμο-αλφα-[2-(διμεθυλαμινο)αιθυλ]-2-μεθοξυ-αλφα-1-ναφθαλινυλ-βητα-φαινυλ-3-κινολινοαιθανολης - Google Patents
Φουμαρικο αλας της (αλφα s, βητα r)-6-βρωμο-αλφα-[2-(διμεθυλαμινο)αιθυλ]-2-μεθοξυ-αλφα-1-ναφθαλινυλ-βητα-φαινυλ-3-κινολινοαιθανοληςInfo
- Publication number
- CY1113594T1 CY1113594T1 CY20121100734T CY121100734T CY1113594T1 CY 1113594 T1 CY1113594 T1 CY 1113594T1 CY 20121100734 T CY20121100734 T CY 20121100734T CY 121100734 T CY121100734 T CY 121100734T CY 1113594 T1 CY1113594 T1 CY 1113594T1
- Authority
- CY
- Cyprus
- Prior art keywords
- alpha
- beta
- phenyl
- methoxy
- ethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06125443 | 2006-12-05 | ||
| EP07847697A EP2086940B1 (en) | 2006-12-05 | 2007-12-03 | Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1113594T1 true CY1113594T1 (el) | 2016-06-22 |
Family
ID=37983588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100734T CY1113594T1 (el) | 2006-12-05 | 2012-08-13 | Φουμαρικο αλας της (αλφα s, βητα r)-6-βρωμο-αλφα-[2-(διμεθυλαμινο)αιθυλ]-2-μεθοξυ-αλφα-1-ναφθαλινυλ-βητα-φαινυλ-3-κινολινοαιθανολης |
Country Status (34)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120010216A1 (en) * | 2010-07-06 | 2012-01-12 | Brown Arthur M | Pharmaceutical compositions containing vanoxerine |
| CZ2014708A3 (cs) | 2014-10-16 | 2016-04-27 | Zentiva, K.S. | Soli Bedaquilinu |
| FI3250182T3 (fi) * | 2015-01-27 | 2023-06-28 | Janssen Pharmaceutica Nv | Dispergoituvia koostumuksia |
| CN106279017A (zh) * | 2015-05-21 | 2017-01-04 | 重庆圣华曦药业股份有限公司 | 贝达喹啉晶型、组合物及其制备方法 |
| CZ2015391A3 (cs) | 2015-06-09 | 2016-12-21 | Zentiva, K.S. | Sůl bedaquilinu s kyselinou citronovou |
| RU2018111482A (ru) * | 2015-10-20 | 2019-11-21 | Чжэцзян Хисунь Фармасьютикал Ко., Лтд. | Кристаллические формы бедаквилин фумарата и способы их получения |
| DK3971177T3 (da) * | 2016-07-20 | 2024-07-15 | Novartis Ag | Aminopyridin-derivater og anvendelse deraf som selektive ALK-2-inhibitorer |
| CN106316943A (zh) * | 2016-07-27 | 2017-01-11 | 重庆华邦制药有限公司 | 富马酸贝达喹啉晶型化合物的精制方法 |
| SI3943070T1 (sl) | 2017-07-14 | 2024-03-29 | Janssen Pharmaceutica Nv, | Dolgo delujoče formulacije bedakilina |
| JP7654544B2 (ja) * | 2018-12-13 | 2025-04-01 | マンカインド コーポレイション | ベダキリンの組成物、それらを含む組み合わせ、それらを調製するための方法、それらを含む使用及び治療方法 |
| WO2020144197A1 (en) | 2019-01-09 | 2020-07-16 | Janssen Pharmaceutica Nv | Combination in the treatment of nontuberculous mycobacterial diseases |
| WO2020161743A1 (en) * | 2019-02-08 | 2020-08-13 | Mylan Laboratories Limited | Process for the preparation of bedaquiline fumarate |
| KR102303635B1 (ko) * | 2020-07-01 | 2021-09-17 | 동아에스티 주식회사 | (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법 |
| CN111888477B (zh) * | 2020-09-15 | 2023-03-07 | 北京福元医药股份有限公司 | 一种贝达喹啉药物制剂 |
| KR20230107275A (ko) | 2020-11-12 | 2023-07-14 | 얀센 파마슈티카 엔.브이. | 비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물 |
| US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
| WO2023150747A1 (en) | 2022-02-07 | 2023-08-10 | Insmed Incorporated | Dry powder compositions of bedaquiline and salts and methods of use thereof |
| WO2023232838A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Pharmaceutica Nv | Bedaquiline for use in the treatment of leprosy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3237575A1 (de) * | 1982-10-09 | 1984-04-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale mopidamolformen |
| GB8824392D0 (en) * | 1988-10-18 | 1988-11-23 | Ciba Geigy Ag | Dispersible formulation |
| TW355683B (en) * | 1994-02-17 | 1999-04-11 | Janssen Pharmaceutica Nv | Composition containing micronized nebivolol |
| WO1998018326A1 (en) | 1996-10-28 | 1998-05-07 | Department Of The Army, U.S. Government | Compounds, compositions and methods for treating antibiotic-resistant infections |
| IL122026A0 (en) * | 1996-10-30 | 1998-03-10 | Lilly Co Eli | Improvements in or relating to the prophylaxis of breast cancer |
| US6819464B2 (en) * | 2002-06-19 | 2004-11-16 | Seiko Epson Corporation | Optical modulator, optical device and projector |
| DK2301544T3 (da) * | 2002-07-25 | 2013-01-02 | Janssen Pharmaceutica Nv | Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer |
| WO2004050068A1 (en) * | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
| EP1753427B1 (en) * | 2004-05-28 | 2008-04-02 | Janssen Pharmaceutica N.V. | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases |
| WO2006024667A1 (en) * | 2004-09-02 | 2006-03-09 | Janssen Pharmaceutica N.V. | Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile |
| JP2006182755A (ja) * | 2004-12-24 | 2006-07-13 | Janssen Pharmaceut Nv | 潜伏性結核の処置 |
-
2007
- 2007-03-12 UA UAA200904218A patent/UA97813C2/uk unknown
- 2007-12-02 JO JO2007511A patent/JO2973B1/en active
- 2007-12-03 EA EA200970532A patent/EA017091B9/ru active Protection Beyond IP Right Term
- 2007-12-03 CN CN201510368829.1A patent/CN105012303A/zh active Pending
- 2007-12-03 NZ NZ576485A patent/NZ576485A/en unknown
- 2007-12-03 PL PL07847697T patent/PL2086940T3/pl unknown
- 2007-12-03 MX MX2009005909A patent/MX2009005909A/es active IP Right Grant
- 2007-12-03 DK DK07847697.5T patent/DK2086940T3/da active
- 2007-12-03 CL CL200703472A patent/CL2007003472A1/es unknown
- 2007-12-03 EP EP07847697A patent/EP2086940B1/en active Active
- 2007-12-03 AU AU2007328945A patent/AU2007328945B2/en active Active
- 2007-12-03 ME MEP-2012-95A patent/ME01456B/me unknown
- 2007-12-03 CN CNA2007800448088A patent/CN101547904A/zh active Pending
- 2007-12-03 PT PT07847697T patent/PT2086940E/pt unknown
- 2007-12-03 SI SI200730984T patent/SI2086940T1/sl unknown
- 2007-12-03 KR KR1020097011043A patent/KR101514700B1/ko active Active
- 2007-12-03 ES ES07847697T patent/ES2387923T3/es active Active
- 2007-12-03 WO PCT/EP2007/063186 patent/WO2008068231A1/en not_active Ceased
- 2007-12-03 CA CA2668512A patent/CA2668512C/en active Active
- 2007-12-03 RS RS20120336A patent/RS52408B/sr unknown
- 2007-12-03 MY MYPI20092284A patent/MY148844A/en unknown
- 2007-12-03 BR BRPI0719693-8A2A patent/BRPI0719693A2/pt not_active Application Discontinuation
- 2007-12-03 US US12/515,986 patent/US8546428B2/en active Active
- 2007-12-03 AP AP2009004870A patent/AP2498A/xx active
- 2007-12-03 JP JP2009539724A patent/JP2010511663A/ja active Pending
- 2007-12-03 HR HRP20120639TT patent/HRP20120639T1/hr unknown
- 2007-12-04 TW TW096146000A patent/TWI417098B/zh active
- 2007-12-05 AR ARP070105442A patent/AR064149A1/es not_active Application Discontinuation
- 2007-12-05 UY UY30762A patent/UY30762A1/es active IP Right Grant
- 2007-12-05 PE PE2007001719A patent/PE20081350A1/es active IP Right Grant
-
2009
- 2009-06-02 IL IL199077A patent/IL199077A/en active IP Right Grant
- 2009-06-04 ZA ZA2009/03907A patent/ZA200903907B/en unknown
- 2009-07-06 NO NO20092535A patent/NO342773B1/no unknown
-
2012
- 2012-08-13 CY CY20121100734T patent/CY1113594T1/el unknown
-
2014
- 2014-09-19 JP JP2014191134A patent/JP5894239B2/ja active Active
-
2016
- 2016-03-04 HK HK16102481.4A patent/HK1214513A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1113594T1 (el) | Φουμαρικο αλας της (αλφα s, βητα r)-6-βρωμο-αλφα-[2-(διμεθυλαμινο)αιθυλ]-2-μεθοξυ-αλφα-1-ναφθαλινυλ-βητα-φαινυλ-3-κινολινοαιθανολης | |
| CY1121017T1 (el) | Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης | |
| CY1122575T1 (el) | Φαρμακοτεχνικες μορφες διστρωματικου δισκιου | |
| CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
| MX384206B (es) | Formulaciones de inhibidores de dpp iv | |
| UY32649A (es) | "sales de 4-(dimetilamino)butil 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato" | |
| CL2007003100A1 (es) | Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria. | |
| ATE526318T1 (de) | Farnesoid-x-rezeptor-agonisten | |
| NO20074823L (no) | Rasagilin-formuleringer med forbedret innholdsensartethet | |
| NO20092611L (no) | Krystallinsk faststoff Rasagilin base | |
| CU23614B7 (es) | Forma cristalina beta del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen | |
| NO20090628L (no) | Pyridizinon derivativater | |
| CY1118731T1 (el) | Φαρμακευτικες συνθεσεις αλβιγλουτιδης | |
| CL2011000589A1 (es) | Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer. | |
| NO20090175L (no) | Stabile laquinimod sammensetninger | |
| CU23616B7 (es) | Forma cristalina gamma del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| EA200870193A1 (ru) | Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение | |
| EA200870217A1 (ru) | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции | |
| CY1109916T1 (el) | Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις | |
| CU23615B7 (es) | Forma cristalina gamma-d del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| UY33075A (es) | Derivados de ciclohexano y usos de los mismos | |
| DOP2010000134A (es) | Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos | |
| UY31860A (es) | Piridinas de tiazolo como inhibidoras de la adn girasa | |
| CY1118976T1 (el) | Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης | |
| EA201290229A1 (ru) | Производные спиролактама и их применение |